[HTML] frontiersin.org

[HTML][HTML] Dendritic cell vaccination of glioblastoma: road to success or dead end

A Datsi, RV Sorg - Frontiers in Immunology, 2021 - frontiersin.org
Glioblastomas (GBM) are the most frequent and aggressive malignant primary brain tumor
and remains a therapeutic challenge: even after multimodal therapy, median survival of …
被引用次数：60 相关文章

Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End

A Datsi, RV Sorg - Frontiers in immunology, 2021 - pubmed.ncbi.nlm.nih.gov
Glioblastomas (GBM) are the most frequent and aggressive malignant primary brain tumor
and remains a therapeutic challenge: even after multimodal therapy, median survival of …

Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End

A Datsi, RV Sorg - The Therapeutic Potential of Antigen …, 2022 - books.google.com
Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End Page 125 REVIEW
published: 02 November 2021 doi: 10.3389/fimmu. 2021.770390 Dendritic Cell Vaccination of …
[HTML] nih.gov

[HTML][HTML] Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End

A Datsi, RV Sorg - Frontiers in Immunology, 2021 - ncbi.nlm.nih.gov
Glioblastomas (GBM) are the most frequent and aggressive malignant primary brain tumor
and remains a therapeutic challenge: even after multimodal therapy, median survival of …

Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End.

A Datsi, RV Sorg - Frontiers in Immunology, 2021 - europepmc.org
Glioblastomas (GBM) are the most frequent and aggressive malignant primary brain tumor
and remains a therapeutic challenge: even after multimodal therapy, median survival of …